跳至主要内容
临床试验/NCT00247026
NCT00247026撤回1 期

A Pilot Study to Determine the Clinical Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes

Hadassah Medical Organization1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2007年4月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
撤回
入组人数
50
试验地点
1
主要终点
major hematologic improvement in any lineage

研究概览

简要总结

To determine the clinical effects of coenzyme Q10 and Curcumin in improving the cytopenias of patients with myelodysplastic syndromes. we propose to explore the efficacy of the natural compounds curcumin and CoQ10 in MDS because these two agents possess many of the effects that are desirable in MDS.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •MDS patients with RA, RARS or RAEB will be eligible for treatment with CoQ10 as long as their IPSS score ≤ 1.5.

排除标准

  • •Pregnant women and nursing women will be excluded.
  • •History of clinically significant liver or kidney disease.
  • •IPSS score >1.5
  • •Poorly controlled diabetes mellitus, hypertension, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to the protocol.

结局指标

主要结局

major hematologic improvement in any lineage

次要结局

  • Time to disease progression
  • Overall and progression-free survival
  • Cytogenetic response

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验